3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Osteosarcoma
2
Neoplasms, Bone Tissue
1
Interventions
Cisplatin
1041
Cyclophosphamide
973
Carboplatin
954
Radiotherapy
893
Bevacizumab
847
Gemcitabine
817
pembrolizumab
759
Paclitaxel
738
Docetaxel
734
Oxaliplatin
706
Capecitabine
649
Fluorouracil
564
Rituximab
559
Nivolumab
506
Dexamethasone
487
Etoposide
468
Doxorubicin
458
Irinotecan
442
Drug Therapy
402
Leucovorin
377
Cytarabine
342
Cetuximab
340
Lenalidomide
326
Trastuzumab
323
Pemetrexed
315
durvalumab
295
Filgrastim
287
Magnetic Resonance Spectroscopy
278
Temozolomide
275
Prednisone
274
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER
×
mifamurtide
×
Clear all
NCT03643133
2026-05-19
SARCOME13
UNICANCER
Phase 2
Active not recruiting
60 enrolled
NCT02441309
2019-09-13
MEMOS
University of Oxford
Phase 2
Terminated
8 enrolled
17 charts